NeurAxis, Inc. Issues Letter To Shareholders From Brian Carrico, President And Chief Executive Officer
Portfolio Pulse from Benzinga Newsdesk
NeurAxis, Inc. (NRXS) issued a shareholder letter highlighting progress since its IPO, including strong med-tech research publications, insurance policy coverage, and revenue growth in Massachusetts and Wisconsin. The company anticipates two new revenue opportunities in 2024: Functional Dyspepsia treatment and an exclusive license for a rectal expulsion device (RED) from the University of Michigan. Both have a $2B market opportunity. NeurAxis is preparing for FDA clearance submissions and expects to surpass 75M covered lives and significant revenue increases in 2024.
December 20, 2023 | 2:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NeurAxis, Inc. has reported significant progress since its IPO, with successful insurance policy coverage leading to revenue growth. It is preparing to introduce new products for Functional Dyspepsia and chronic constipation, both with substantial market opportunities, and expects to see a significant increase in covered lives and revenues in 2024.
The positive developments reported by NeurAxis, including insurance coverage, revenue growth, and the anticipation of new revenue streams from upcoming products, are likely to be viewed favorably by investors. The company's strategic positioning and clear targets for 2024 suggest potential for stock price appreciation in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100